Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.
GF120918 (Elacridar) is a very potent inhibitor of the ABC transporters MDR-1 (P-gp) and BCRP. GF120918 increases the bioavailability of cytotoxic anti-tumor drugs, and also leads to increased levels of anti-HIV drugs in the brain and CNS.
GF120918 (Elacridar) is an inhibitor of MDR-1 (P-gp).
buy Elacridar (GF120918) | Elacridar (GF120918) supplier | purchase Elacridar (GF120918) | Elacridar (GF120918) cost | Elacridar (GF120918) manufacturer | order Elacridar (GF120918) | Elacridar (GF120918) distributor
Elacridar | GF120918 | GW0918 | GG918 | GW120918 | ABC transporters MDR-1 (P-gp) inhibitor | N-[4-[2-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]-9,10-dihydro-5-methoxy-9-oxo-4-acridinecarboxamide